STOCK TITAN

Inogen (INGN) director receives 28,081-share restricted stock unit grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Ladone Mary Kay reported acquisition or exercise transactions in this Form 4 filing.

Inogen Inc director Mary Kay Ladone received a grant of 28,081 shares of common stock through a restricted stock unit award. After this compensation grant, she directly holds 104,966 shares. The RSUs will vest on the earlier of one year from grant or the day before the next annual stockholders meeting, assuming she continues in service.

Positive

  • None.

Negative

  • None.
Insider Ladone Mary Kay
Role null
Type Security Shares Price Value
Grant/Award Common Stock 28,081 $0.00 --
Holdings After Transaction: Common Stock — 104,966 shares (Direct, null)
Footnotes (1)
  1. [object Object]
RSU grant size 28,081 shares Restricted stock unit award to director Mary Kay Ladone
Post-grant holdings 104,966 shares Total common shares held directly after the award
Grant price per share $0.00 per share Equity compensation, not an open-market purchase
Vesting condition Earlier of 1 year or before next annual meeting Requires continued service until vesting date
restricted stock unit award financial
"The reported shares were acquired pursuant to a restricted stock unit award."
A restricted stock unit award is a promise by a company to give an employee a specified number of company shares at a future date if certain conditions are met, such as staying with the company or hitting performance goals. For investors, these awards matter because they can increase the total number of shares outstanding when converted, diluting existing holders, and they align employees’ incentives with shareholders’ interests much like giving a rising bonus that becomes real only after conditions are satisfied.
vest financial
"the restricted stock unit award shall vest on the earlier of (i) the one-year anniversary..."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ladone Mary Kay

(Last)(First)(Middle)
C/O INOGEN, INC.
500 CUMMINGS CENTER, SUITE 2800

(Street)
BEVERLY MASSACHUSETTS 01915

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Inogen Inc [ INGN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/05/2026A28,081(1)A$0104,966D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The reported shares were acquired pursuant to a restricted stock unit award. Subject to the reporting person's continued service, the restricted stock unit award shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the date of the Annual Meeting of the Issuer's stockholders next following the date of grant.
/s/ Mary Wright, as Attorney-in-Fact06/09/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Inogen (INGN) director Mary Kay Ladone report on this Form 4?

Mary Kay Ladone reported receiving 28,081 shares of Inogen common stock via a restricted stock unit award. This is a compensation-related acquisition, not an open-market purchase or sale, and increases her directly held position to 104,966 shares after the grant.

How many Inogen shares does Mary Kay Ladone hold after this RSU grant?

After the reported restricted stock unit grant of 28,081 shares, Mary Kay Ladone holds 104,966 Inogen common shares directly. This total reflects her updated ownership position following the award as disclosed in the Form 4 filing.

How do the new Inogen restricted stock units for Mary Kay Ladone vest?

The restricted stock unit award vests on the earlier of one year from the grant date or the day before the next annual meeting of Inogen stockholders. Vesting is conditioned on Mary Kay Ladone’s continued service with the company through that vesting date.

Was Mary Kay Ladone’s Inogen share transaction a market buy or sell?

The transaction was not a market buy or sell. It was an acquisition coded as a grant or award, with a price per share of $0.00, reflecting equity compensation rather than an open-market trade in Inogen shares.

What does the zero price per share mean in Mary Kay Ladone’s Inogen Form 4?

The reported transaction price of $0.00 per share indicates a stock-based compensation grant rather than a cash purchase. The 28,081 restricted stock units were awarded to Mary Kay Ladone as part of her director compensation, subject to future vesting conditions.